Axcella Health Inc Quick Ratio (AXLA) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Axcella Health Inc   (NASDAQ: AXLA)

Axcella Health Inc 's Quick Ratio

AXLA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 0.88 below Axcella Health Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 156 other companies have achieved higher Quick Ratio than Axcella Health Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 1492 to 2411.

Explain Quick Ratio?
How much Cash & cash equivalents AXLA´s has?
What are AXLA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AXLA Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change -35.27 % -10.78 % 23.7 % 185.03 % 30.28 %
Y / Y Cash & cash equivalent Change -79.99 % -80.16 % -31.88 % -61.56 % -43.76 %
Quick Ratio MRQ 0.88 1.22 1.37 1.15 2.83
AXLA's Total Ranking # 2411 # 1492 # 1597 # 1931 # 1179
Seq. Current Liabilities Change -1.01 % -18.34 % -43.21 % 41.03 % 36.43 %
Seq. Cash & cash equivalent Change -29.15 % -26.87 % -32.56 % -42.74 % -29.77 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 157
Healthcare Sector # 845
Overall Market # 2411


Quick Ratio Statistics
High Average Low
8.53 2.27 0.02
(Sep 30 2021)   (Sep 30 2019)




Financial Statements
Axcella Health Inc 's Current Liabilities $ 10 Millions Visit AXLA's Balance sheet
Axcella Health Inc 's Cash & cash equivalent $ 9 Millions Visit AXLA's Balance sheet
Source of AXLA's Sales Visit AXLA's Sales by Geography


Cumulative Axcella Health Inc 's Quick Ratio

AXLA's Quick Ratio for the trailling 12 Months

AXLA Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 22.16 % 46.25 % 53 % 56.19 % 26.71 %
Y / Y Cash & cash equivalent TTM Growth -67.83 % -57.38 % -31.78 % -31.43 % 18.42 %
Quick Ratio TTM 1.16 1.64 2.43 2.66 4.41
Total Ranking TTM # 4160 # 4024 # 3639 # 3947 # 3822
Seq. Current Liabilities TTM Growth -9.12 % -2 % 4.05 % 31.84 % 8.79 %
Seq. Cash & cash equivalent TTM Growth -35.69 % -33.74 % -5.07 % -20.47 % -14.79 %

Quick ratio ranking by company, industry and sector >> Back to AXLA Financial Strength Comparisons >> Go to Compare AXLA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in AXLA's Current Liabilities to $10.15 millions, cumulative Quick Ratio to 1.16 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 172 other companies have achieved higher Quick Ratio than Axcella Health Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 4024 to 4160.

Explain Quick Ratio?
How much Cash & cash equivalents AXLA´s has?
What are AXLA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 173
Healthcare Sector # 1095
Within the Market # 4160


trailing twelve months Quick Ratio Statistics
High Average Low
3 0.99 0.01
(Mar 31 2022)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Genetic Technologies Limited  2.37 $ 5.231  Millions$ 2.207  Millions
Enzo Biochem Inc  2.11 $ 82.373  Millions$ 39.009  Millions
Protalix Biotherapeutics inc   2.09 $ 48.184  Millions$ 23.109  Millions
Atara Biotherapeutics Inc   2.06 $ 153.642  Millions$ 74.552  Millions
Relay Therapeutics Inc   2.04 $ 145.902  Millions$ 71.576  Millions
Genfit S a   2.02 $ 87.124  Millions$ 43.098  Millions
Amgen Inc   2.00 $ 34,248.000  Millions$ 17,097.000  Millions
Gamida Cell Ltd   1.96 $ 101.634  Millions$ 51.820  Millions
Halozyme Therapeutics Inc   1.90 $ 221.165  Millions$ 116.393  Millions
Nanostring Technologies Inc   1.84 $ 114.930  Millions$ 62.433  Millions
Innate Pharma Sa  1.78 $ 79.078  Millions$ 44.393  Millions
Vaxart Inc   1.77 $ 24.628  Millions$ 13.883  Millions
Tradeup Acquisition Corp  1.73 $ 2.479  Millions$ 1.431  Millions
Seagen Inc   1.69 $ 1,292.119  Millions$ 762.898  Millions
Bio techne Corp  1.68 $ 204.310  Millions$ 121.778  Millions
Neurocrine Biosciences Inc   1.68 $ 976.700  Millions$ 582.500  Millions
Ladrx Corporation  1.64 $ 3.603  Millions$ 2.201  Millions
Cidara Therapeutics Inc   1.61 $ 50.430  Millions$ 31.420  Millions
Tectonic Therapeutic Inc   1.59 $ 14.932  Millions$ 9.414  Millions
Qiagen N v   1.57 $ 1,057.782  Millions$ 672.125  Millions
Adma Biologics Inc   1.53 $ 62.513  Millions$ 40.830  Millions
Argenx Se  1.52 $ 1,110.567  Millions$ 732.978  Millions
Aptose Biosciences Inc   1.51 $ 17.482  Millions$ 11.585  Millions
Repligen Corp  1.44 $ 603.656  Millions$ 419.522  Millions
Erytech Pharma S a   1.41 $ 27.506  Millions$ 19.525  Millions
Cel sci Corporation  1.41 $ 7.454  Millions$ 5.293  Millions
Eiger Biopharmaceuticals Inc   1.40 $ 22.983  Millions$ 16.392  Millions
Meiragtx Holdings Plc  1.29 $ 92.773  Millions$ 71.803  Millions
Biocardia Inc   1.19 $ 4.305  Millions$ 3.616  Millions
Biogen Inc   1.09 $ 3,460.500  Millions$ 3,186.500  Millions

Date modified: 2026-08-29T17:40:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.